Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Radiotherapy is required to overcome pain and to evoke recalcification in multiple myeloma (MM) patients. Approximately 70% of all MM patients receive one or more radiotherapies in the course of their illness. The relief of pain is obtained in 75 - 100%. Recalcification is achieved in 40 - 50% of the irradiated bone destructions.There were a lot of randomized trials showed the same effect of single (SF) and multiple fractions (MF) in pain relief and recalcification for patients with painful bone metastases from solid tumors. The role of different palliative radiotherapeutic regimens for MM is not well established due to lack of clinical trials. Our prospective study analyzed the effect of two different radiotherapeutic regimens in the treatment of MM on pain relief, analgesics consumption and recalcification.
The primary aim of our prospective study is to analyzed the effect of two different radiotherapeutic regimens in the treatment of MM on pain relief, the secondary aim is to analyzed the effect of two different radiotherapeutic regimens in the analgesics consumption and recalcification.
Eligibility criteria are age more than 18 years, Karnofsky index more than 40%, patients with painful bone destructions, patients with impending fracture in the region of destructions.
Exclusion Criteria are: patients with bone metastases from solid tumors, patients with solitary plasmacytoma, patients who had received previous irradiation to the present painful destruction site, patients who were incapable to complete the quality of life questionnaires, patients with poor health status.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| External Beam radiotherapy | Experimental | Single 8 Gy fraction |
|
| 3 Gy x 10 fractions | Active Comparator | External Beam radiotherapy - total dose 30 Gy, 3 Gy per fraction. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| External Beam radiotherapy | Radiation | External Beam radiotherapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| To analyzed the pain relief in visual analogue scalewith the scale endpoints from 0 to 10 of two different radiotherapeutic regimens. | At admission and after 4, 12 and 24 weeks after radiotherapy |
| Measure | Description | Time Frame |
|---|---|---|
| To analyzed the analgesics consumption in two different radiotherapeutic regimens arms. | At admission and after 4, 12 and 24 weeks after radiotherapy |
| Measure | Description | Time Frame |
|---|---|---|
| To analyzed the recalcification on X rays in two different radiotherapeutic regimens arms. | At admission and after 4, 12 and 24 weeks after radiotherapy |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oncology Institute of Lithuanian of Health Sciences | Kaunas | 50009 | Lithuania |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41832666 | Derived | Rudzianskiene M, Inciura A, Gerbutavicius R, Rudzianskas V, Ugenskiene R, Paukstaitiene R, Dambrauskiene R, Vaitiekus D, Kulboke M, Juozaityte E. The influence of polymorphisms in cytokine genes on pain and response to palliative radiotherapy in multiple myeloma patients: prospective observational study. Scand J Pain. 2026 Mar 13;26(1). doi: 10.1515/sjpain-2025-0013. eCollection 2026 Jan 1. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided